Press release
Oncopeptides publishes the 2022 Annual Report
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces that the 2022 Annual Report has been published.
2022 was a landmark year for Oncopeptides. The company received a full marketing authorization for Pepaxti in Europe and initiated a launch of the drug in Germany. The commercialization enables us to bring hope to patients with multiple myeloma who despite the introduction of novel therapies need an accessible treatment option that offers robust efficacy, reduces treatment burden, and maintains quality of life.
“Since starting as CEO in January 2023, I have been impressed by our driven, experienced team and excited about the opportunity we have with Pepaxti. As we move forward, we have clear corporate goals which are aligned to our value drivers,” says Monica Shaw, CEO, Oncopeptides. “Our key priority for 2023 is to raise awareness and willingness to prescribe Pepaxti and ensure that we have the financial discipline needed to maximize our investments. “
The 2022 Annual Report is available as a pdf document on the website under Financial reports.